Companies › EicOsis Human Health
1 active drug program in 3 registered trials: 3 Phase 1; Neurology, Genitourinary; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EC5026 Soluble epoxide hydrolase (sEH) inhibitor | EPHX2 | Phase 1 | Parkinson's Disease (PD); Chronic Kidney Disease; Spinal Cord Injuries | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07142044 | EC5026 | Phase 1 | Parkinson's Disease (PD) | Neurology | Dec 2026 |
| NCT07694544 | EC5026 | Phase 1 | Chronic Kidney Disease | Genitourinary | Dec 2026 |
| NCT06438471 | EC5026 | Phase 1 | Spinal Cord Injuries | Neurology | Dec 2027 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.